Instead, there were frequent inactivating mutations in ATRX known to cause alternative lengthening of telomeres (ALT) in five of the de novo RRD glioblastomas (5/9, 56%), which were rare in the conventional glioblastoma cohort (4/450, 1%). The gene discussed is ATRX; the disease is glioblastoma.